Member Info for Timster

That's going to be a real pain be 9pm over there when trading opens. Not like the yanks with thier 2.30 start :)

knob

a MASSIVE tick in the affimer box

its all Energyshares work I just thought it needed a new thread at the top of the board

we all know the potential is mind blowing, lets talk about that instead of other ****e companies. I know this is stolen from another thread but it needs to be at the top of the board:
Avacta has 34 yes 34 chances of a blockbuster product and they are still coming.
Affimer tech can propel Avacta into Blockbuster sales.
Major Pharms & Diagnostics firms have licences and products with Avacta
Daewoong,Moderna,LG Chem,Bruker,ADC,Point,BioKit
Astrea,Mologic,Deepverge,Tufts, the more companies that licence affimers the harder and more costly it will be to buy out Avacta.
Oncology x 11
Ava6000,AVA7500,
AVA028,AVA7000,AVA004
AVA027,AVA3996 plus 4 undisclosed targets
Covid x 5
Affidx, Bams,Elisa,
Saliva,Spitaffidx (You can have that one Big Al)
Mologic combination test.
Plus in house pipe line non-COVID diagnostic tests, which include assays for D-dimer, cortisol, vitamins D and B12 and CRP.
LG Chem x 8
Every RNS states a multi-target deal with LG Chem worth up to $400m.
In the business update $98 million for the 2 below and up to $55m for each new product
So LG Chem has potentially 8 new products.
multi-target collaboration with LG Chem incorporating Avacta's Affimer XT™ serum half-life extension and LG Chem has Affimer PD-L1 inhibitortotalling $98million
The expanded partnership also provides LG Chem with rights to develop and commercialise other Affimer and non-Affimer biotherapeutics combined with Affimer XT half-life extension for a range of indications and Avacta could earn an additional $55m in milestone payments for each of these new products.
Daewoong x 2
Gene & stem cell with other targets
Point x 1
radiopharmaceutical prodrug
ADC x 3
three undisclosed cancer targets and provide these to ADC Therapeutics
Moderna x 1
exclusive license agreement with respect to certain Affimer molecules
BioKit x1
Royalty bearing license agreement to develop and commercialise an Affimer®-based in-vitro diagnostic test
Astrea x 1
Deepverge x 1

look at the list who think Avacta have quality tech worth investing in:
ModernaTX
Bruker
LG Chem
Daewoong Pharmaceutical
BioKit

and those are just the large ones worth billions of pounds in their own right

lovely

GKB, mumbo, always whining and decorum, winnifreth et al, don't like it!

From AVACTA:

on the basis of these excellent initial data, the Group will now progress to a full clinical validation with a larger number of patient samples to CE mark the test for professional use, aiming to bring the test to market in Europe around the end of the first quarter of this year.

If tech transfer hadn't started that would be impossible

Add BioKit to the list :)

Did you jump aboard, or were you a " a bit concerned" by the " bit concerned "holders?

That'll be dumbo! although he wants to wait till 10 quid to buy in ...... clown

Imagine what it will be like when we get clinical validation finished the CE marking, BAMS validated, then contract figures released in the UK, then contract figures released for the rest of the world, then affirmer licensing for other test manufacturers, then ava6000 trailed in patients.......

he can afford 2 shares now, but we are rising so he needs to work hard to get to 3

its mumbo he's doing such a quality deramp job :)

£5

Next up CE marking, or maybe BAMS

.

class Mumbo, almost sounds like someone else wrote that for you.....

all good for Avacta and has Larsh says the combination of Mologic and Avacta could hit the 100/100 test. But that's for the next round of 3rd Gen release